CompletedPhase 2NCT03118674
Harvoni Treatment Porphyria Cutanea Tarda
Studying Disorder of porphyrin and heme metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wake Forest University Health Sciences
- Principal Investigator
- Herbert L Bonkovsky, MDWake Forest University Health Sciences
- Intervention
- Harvoni(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (3)
- University of California, San Francisco, San Francisco, California, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- University of Texas Medical Branch, Galveston, Texas, United States
Collaborators
Gilead Sciences · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institutes of Health (NIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03118674 on ClinicalTrials.govOther trials for Disorder of porphyrin and heme metabolism
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06910358Study of Bitopertin in Participants With EPP or XLP (APOLLO)Disc Medicine, Inc
- ENROLLING BY INVITATIONPHASE2NCT06971900GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic ProtoporphyriaPortal Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02935400Acute Porphyria Biomarkers for Disease ActivityThe University of Texas Medical Branch, Galveston
- ACTIVE NOT RECRUITINGNCT01617642Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Nordlandssykehuset HF
See all trials for Disorder of porphyrin and heme metabolism →